Prof. Yimin Zhu , Suzhou Institute of Nanotechnology, Chinese Academy of Sciences , China
Prof. Yimin Zhu is a distinguished researcher in bioengineering, specializing in cancer therapies, biomaterials, and peptide screening platforms. With a background in both clinical medicine and biotechnology, she bridges the gap between medical applications and cutting-edge biotechnological innovations. Prof. Zhu completed her master’s in Clinical Medicine from Tianjin Medical University in 1996 and a Ph.D. in Biochemistry from the National University of Singapore in 2005. She has made significant contributions to cancer immunotherapy, drug delivery systems, and biomarker identification. Prof. Zhu’s work has led to over 30 first-author/co-corresponding publications in leading scientific journals, and she holds more than 20 patents. She currently holds a professorship at Suzhou Institute of Nano-Tech and Nano-Bionics, CAS, where her research continues to advance cancer treatments through novel molecular mechanisms and drug delivery platforms.
Publication Profile:
Scopus
Strengths for the Award:
- Interdisciplinary Expertise: Prof. Yimin Zhu has a unique blend of clinical medicine and advanced biotechnology expertise, making her well-suited to bridge the gap between medical practice and cutting-edge cancer research. Her background in both the clinical and research fields allows her to tackle cancer therapies from multiple angles.
- Impactful Research: Prof. Zhu’s research focuses on critical areas in cancer therapy, such as peptide-based immunotherapy, tumor mechanisms, drug delivery systems, and biomarker discovery. She has published over 30 high-impact papers in leading journals, showcasing her leadership in the field.
- Innovative Contributions: She has made substantial contributions to developing peptide-based bispecific CAR T cells and innovative drug delivery systems, with several patents granted. These innovations hold great promise for advancing cancer therapy and improving patient outcomes.
- Support and Funding: Prof. Zhu has successfully secured substantial research funding, including multiple grants from the National Natural Science Foundation of China, supporting her groundbreaking research in cancer immunotherapy and biomaterial development.
Areas for Improvement:
- Broader Outreach: Although Prof. Zhu has made impressive advancements in cancer research, expanding her work’s visibility to a broader audience in the medical and biotechnology communities, as well as among the general public, could increase the impact of her innovations.
- Collaboration and Mentorship: Further expanding interdisciplinary collaborations, particularly with social scientists or clinicians in oncology, could strengthen the practical application of her research and increase its translation into clinical practice. Additionally, mentoring young women in STEM could increase her contribution to fostering diversity in the field.
- Public Engagement: Enhancing communication efforts to present her research in a more accessible format for non-experts could be a significant avenue for impact, particularly in terms of attracting additional funding and public interest in her cancer-focused work.
Education:
Prof. Yimin Zhu’s educational journey reflects her interdisciplinary approach to bioengineering and medical science. She earned her Master’s degree in Clinical Medicine from Tianjin Medical University in 1996, where she initially focused on medical practice, gaining hands-on experience as a resident and consultant in Neurology. Her passion for scientific research led her to pursue a Ph.D. in Biochemistry from the National University of Singapore, completed in 2005. This transition to biochemistry allowed her to explore molecular biology, cancer research, and biotechnology. Prof. Zhu’s postdoctoral work at the University of California, Santa Barbara, in Chemical Engineering, further honed her expertise in nanotechnology, bioengineering, and therapeutic innovations. This broad educational foundation, combining clinical experience with cutting-edge research, has uniquely positioned her as a leader in cancer bioengineering and drug delivery systems.
Experience:
Prof. Yimin Zhu’s diverse experience spans both clinical medicine and high-impact research. Between 1996 and 2000, she worked as a resident and consultant doctor in Neurology, which provided a strong foundation in patient care and medical science. Transitioning to research, she served as a research fellow at the National University of Singapore from 2003 to 2005, focusing on biochemistry and cancer-related molecular mechanisms. Prof. Zhu further developed her expertise during her postdoctoral training in the Chemical Engineering Department at the University of California, Santa Barbara, where she explored the intersection of chemical engineering, nanotechnology, and therapeutic interventions. Since joining the Suzhou Institute of Nano-Tech and Nano-Bionics in 2008, she has been a professor, where she leads innovative research in peptide-based cancer therapies, immunotherapy, and drug delivery systems. Her extensive academic background and practical experience have earned her numerous patents and substantial research funding.
Research Focus:
Prof. Yimin Zhu’s research primarily focuses on bioengineering for cancer treatment, peptide screening platforms, and targeted drug delivery systems. Her work involves identifying molecular mechanisms behind tumor cell behavior and developing innovative methods for cancer diagnosis and therapy. She is dedicated to advancing cancer immunotherapy, particularly through the development of peptide-based bispecific CAR T cells targeting key proteins like EGFR and tumor stroma. Prof. Zhu’s research aims to enhance the efficacy of cancer treatments while minimizing side effects. Her studies also explore the development of smart delivery systems, such as extracellular vesicle-based nanodrugs, to improve the precision and effectiveness of drug delivery to tumor sites. Additionally, her work delves into the identification of cancer biomarkers, offering new ways to predict tumor metastasis and optimize treatment regimens. By combining molecular biology, nanotechnology, and biotechnology, Prof. Zhu’s research holds great promise for advancing personalized cancer care.
Publications Top Notes:
- The peptide-based bispecific CAR T cells target EGFR and tumor stroma for effective cancer therapy 🧬
- Develop a PD-1-blockade peptide to reinvigorate T-cell activity and inhibit tumor progress 💉
- Natural killer cells contribute to ‘hot’ tumor regression in the allergic inflammatory environment 🦠
- Identification of cancer protein biomarker based on cell specific peptide and its potential role in predicting tumor metastasis 🔬
- Extracellular Vesicle‐Based Nanodrug Delivery 💊
- Inhibition of Autophagy Promotes the Elimination of Liver Cancer Stem Cells by CD133 Aptamer-Targeted Delivery of Doxorubicin 🧫
- Dermatophagoides pteronyssinus allergen Der p 22: Cloning, expression, IgE-binding in asthmatic children, and immunogenicity 🌿
- Reforming the Chimeric Antigen Receptor by Peptide Towards Optimized CAR T Cells With Enhanced Anti-Cancer Potency and Safety 🦠
- Smart delivery of poly-peptide composite for effective cancer therapy 💡
- The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells ⚙️
Conclusion:
Prof. Yimin Zhu’s research excellence, particularly in cancer therapy, peptide-based immunotherapy, and novel drug delivery systems, positions her as a highly deserving candidate for the Research for Women Researcher Award. Her interdisciplinary approach, groundbreaking innovations, and leadership in publishing high-impact scientific papers make her a trailblazer in the field of bioengineering. By addressing the areas for improvement, particularly in outreach and mentorship, Prof. Zhu could amplify her contributions even further, inspiring the next generation of women scientists and advancing the fight against cancer.